Nanomedicine combats drug resistance in lung cancer
Lung cancer is the second most prevalent cancer and the leading cause of cancer‐related
death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, and …
death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, and …
[HTML][HTML] The predictive and prognostic role of RAS–RAF–MEK–ERK pathway alterations in breast cancer: revision of the literature and comparison with the analysis of …
Simple Summary The RAS/RAF/MEK/ERK pathway is implicated in fundamental processes
frequently altered in tumors, such as cell proliferation and survival. In breast cancer, it is …
frequently altered in tumors, such as cell proliferation and survival. In breast cancer, it is …
[HTML][HTML] Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
M Holderfield, BJ Lee, J Jiang, A Tomlinson… - Nature, 2024 - nature.com
Abstract RAS oncogenes (collectively NRAS, HRAS and especially KRAS) are among the
most frequently mutated genes in cancer, with common driver mutations occurring at codons …
most frequently mutated genes in cancer, with common driver mutations occurring at codons …
[HTML][HTML] Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
The relevance of KRAS mutation alleles to clinical outcome remains inconclusive in
pancreatic adenocarcinoma (PDAC). We conducted a retrospective study of 803 patients …
pancreatic adenocarcinoma (PDAC). We conducted a retrospective study of 803 patients …
[HTML][HTML] In silico strategies for designing of peptide inhibitors of oncogenic K-ras G12V mutant: inhibiting cancer growth and proliferation
Simple Summary The most well-known oncogene and one with the highest rates of mutation
across all cancers is K-Ras, also known as the Kirsten rat sarcoma viral oncogene …
across all cancers is K-Ras, also known as the Kirsten rat sarcoma viral oncogene …
[HTML][HTML] Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
KRAS G12C mutations are critical in the pathogenesis of multiple cancer types, including
non-small cell lung (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal …
non-small cell lung (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal …
Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido [4, 3-d] pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent …
X Xiao, J Feng, J Ma, X Xia, X Liu, J Zhang… - Journal of Medicinal …, 2023 - ACS Publications
The breakthrough in drug development of KRASG12C inhibitors provides inspiration for
targeting alternative KRAS mutations, especially the most prevalent KRASG12D variant …
targeting alternative KRAS mutations, especially the most prevalent KRASG12D variant …
RHOAL57V drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling
Cancer-associated mutations in the guanosine triphosphatase (GTPase) RHOA are found at
different locations from the mutational hotspots in the structurally and biochemically related …
different locations from the mutational hotspots in the structurally and biochemically related …
[HTML][HTML] Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity
AA Wurm, S Brilloff, S Kolovich, S Schäfer… - Cell Reports …, 2023 - cell.com
Targeted therapies are effective in treating cancer, but success depends on identifying
cancer vulnerabilities. In our study, we utilize small RNA sequencing to examine the impact …
cancer vulnerabilities. In our study, we utilize small RNA sequencing to examine the impact …
[HTML][HTML] Targeting the 'Undruggable'Driver protein, KRAS, in epithelial cancers: Current perspective
This review summarizes recent development in synthetic drugs and biologics targeting
intracellular driver genes in epithelial cancers, focusing on KRAS, and provides a current …
intracellular driver genes in epithelial cancers, focusing on KRAS, and provides a current …